,Request: Request Number  ↑,Product,DOC ID,Question,accuracy,extracted_sentence_1,keywords_1,Document_Name_1,DOC_ID_1,new_keywords_1,score_1,extracted_sentence_2,keywords_2,Document_Name_2,DOC_ID_2,new_keywords_2,score_2,extracted_sentence_3,keywords_3,Document_Name_3,DOC_ID_3,new_keywords_3,score_3
0,REQ-29479,Wegovy,SEOB 111,Please email Dr. Luu Sema 2.4mg Overview for his plan’s review. Infographics when available.,not accurate,email dr luu sema 24 mg overview plan review infograph avail,"overview,approval,summary",Approval and Product Overview (SEOB 010) (v3.0),SEOB 010,"overview , approv , summari",33.33333333,email dr luu sema 24 mg overview plan review infograph avail,"medicaid,formulary,summary,overview",Wegovy Medicaid Summary (SEOB 400) (v2.0),SEOB 400,"medicaid , formulari , summari , overview",25,email dr luu sema 24 mg overview plan review infograph avail,"step,overview,slide,clinical,pi",Clinical Overview of Wegovy (SEOB 601) (v1.0),SEOB 601,"step , overview , slide , clinic , pi",20
1,REQ-42253,Ozempic,SEM 032,"Provider has a patient with type 2 diabetes who was diagnosed with a benign tumor on the pancreas. She wanted to find out if we have any studies that included patients with the same condition, and is it safe to start them on Ozempic?",not accurate,provid patient type 2 diabet diagnos benign tumor pancrea want find studi includ patient condit    safe start ozemp,"type 1,diabetes,t1dm,t1d",Type 1 Diabetes (SEM 090) (v12.0),SEM 090,"type 1,diabet , t1 dm , t1d",25,provid patient type 2 diabet diagnos benign tumor pancrea want find studi includ patient condit    safe start ozemp,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,provid patient type 2 diabet diagnos benign tumor pancrea want find studi includ patient condit    safe start ozemp,"pancreatitis,pancreas,amylase,lipase,pancreatic,enzymes",Pancreatitis (SEM 006) (v14.0),SEM 006,"pancreat , pancrea , amylas , lipas , pancreat , enzym",20
2,REQ-43085,Ozempic,SEM 134,Is there any reason you would not want to use Ozempic in a younger patient with Type 2 diabetes due to increased risk of cancer or other long term issues?,accurate with one of docID,reason want use ozemp young patient type 2 diabet increas risk cancer long term issu,"neoplasms,cancer,neoplasm",Neoplasms  (SEM 134) (v7.0),SEM 134,"neoplasm , cancer , neoplasm",50,reason want use ozemp young patient type 2 diabet increas risk cancer long term issu,"type 1,diabetes,t1dm,t1d",Type 1 Diabetes (SEM 090) (v12.0),SEM 090,"type 1,diabet , t1 dm , t1d",25,reason want use ozemp young patient type 2 diabet increas risk cancer long term issu,"long-term,longest,duration,longer,time",Long-Term Data (SEM 174) (v5.0),SEM 174,"long - term , long , durat , long , time",25
3,REQ-43155,Ozempic,SEM 601,Please email me a copy of the updated Ozempic on label slide deck.,accurate with one of docID,email copi updat ozemp label slide deck,"clinical,overview,slide,slides,deck",Clinical Overview of Ozempic (SEM 601) (v4.0),SEM 601,"clinic , overview , slide , slide , deck",50,email copi updat ozemp label slide deck,"sustain,overview,slide,slides,clinical",Cover to Ozempic Clinical Overview Deck (SEM 600) (v5.0),SEM 600,"sustain , overview , slide , slide , clinic",25,email copi updat ozemp label slide deck,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25
4,,Ozempic,SEM 600,Please email me a copy of the updated Ozempic on label slide deck.,accurate with one of docID,email copi updat ozemp label slide deck,"clinical,overview,slide,slides,deck",Clinical Overview of Ozempic (SEM 601) (v4.0),SEM 601,"clinic , overview , slide , slide , deck",50,email copi updat ozemp label slide deck,"sustain,overview,slide,slides,clinical",Cover to Ozempic Clinical Overview Deck (SEM 600) (v5.0),SEM 600,"sustain , overview , slide , slide , clinic",25,email copi updat ozemp label slide deck,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25
5,REQ-43318,Ozempic,SEM 122,Christina would like to know if there is data on a tapering effect of weight loss seen with OZEMPIC.,not accurate,christina like know datum taper effect weight loss see ozemp,"mechanism,weight,weight loss",Mechanism of Weight Loss (SEM 141) (v6.0),SEM 141,"mechan , weight , weight loss",66.66666667,christina like know datum taper effect weight loss see ozemp,"weight,victoza",Weight vs. Victoza (SEM 142) (v6.0),SEM 142,"weight , victoza",50,christina like know datum taper effect weight loss see ozemp,"obesity,weight",Obesity Indication (SEM 155) (v13.0),SEM 155,"obes , weight",50
6,REQ-43325,Ozempic,SEM 1000,Is there any data showing Ozempic in use for patients who have neuroendocrine tumors of the GI tract?,not accurate,datum show ozemp use patient neuroendocrin tumor gi tract,"gastrointestinal,gi,management,ae",Management of GI Adverse Events (GLP1 014) (v1.0),GLP1 014,"gastrointestin , gi , manag , ae",25,datum show ozemp use patient neuroendocrin tumor gi tract,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,datum show ozemp use patient neuroendocrin tumor gi tract,"gi,gastrointestinal,safety,ae,adverse events",GI Adverse Events (SEM 005) (v11.0),SEM 005,"gi , gastrointestin , safeti , ae , advers event",20
7,REQ-43330,Ozempic,SEM 1000,"Dr. Jentner would like to know if the Ozempic pens are bio-degradable or if they can be recycled.  She would like to know if the pen needs/can be disposed of in a sharps container,if it doesn’t  have a needle attached.",not accurate,dr jentner like know ozemp pen biodegrad recycl    like know pen need dispos sharp contain nt    needl attach,"nnt,number,needed,treat",Number Needed to Treat (NNT) in SUSTAIN 6 (SEM 161) (v6.0),SEM 161,"nnt , number , need , treat",25,dr jentner like know ozemp pen biodegrad recycl    like know pen need dispos sharp contain nt    needl attach,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,dr jentner like know ozemp pen biodegrad recycl    like know pen need dispos sharp contain nt    needl attach,"ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,"ozemp , glucos , semaglutid , fast , fpg , preprandi",16.66666667
8,REQ-43341,Ozempic,SEM 125,"Can you send me any information on Ozempic’s impact on hypoglycemia, creatinine levels, and/or overall kidney function in patients with CKD stage 4 vs. stage 5?",not accurate,send inform ozemp impact hypoglycemia    creatinin level    overal kidney function patient ckd stage 4 vs stage 5,"hypoglycemia,hypo,safety",Hypoglycemia (SEM 120) (v9.0),SEM 120,"hypoglycemia , hypo , safeti",66.66666667,send inform ozemp impact hypoglycemia    creatinin level    overal kidney function patient ckd stage 4 vs stage 5,"flow,renal,kidney",The FLOW Trial (SEM 183) (v2.0),SEM 183,"flow , renal , kidney",33.33333333,send inform ozemp impact hypoglycemia    creatinin level    overal kidney function patient ckd stage 4 vs stage 5,"renal,kidney,outcomes,creatinine,uar,scr,glomerular,gfr",Renal Outcomes (GLP1 012) (v2.0),GLP1 012,"renal , kidney , outcom , creatinin , uar , scr , glomerular , gfr",25
9,,Ozempic,SEM 126,"Can you send me any information on Ozempic’s impact on hypoglycemia, creatinine levels, and/or overall kidney function in patients with CKD stage 4 vs. stage 5?",not accurate,send inform ozemp impact hypoglycemia    creatinin level    overal kidney function patient ckd stage 4 vs stage 5,"hypoglycemia,hypo,safety",Hypoglycemia (SEM 120) (v9.0),SEM 120,"hypoglycemia , hypo , safeti",66.66666667,send inform ozemp impact hypoglycemia    creatinin level    overal kidney function patient ckd stage 4 vs stage 5,"flow,renal,kidney",The FLOW Trial (SEM 183) (v2.0),SEM 183,"flow , renal , kidney",33.33333333,send inform ozemp impact hypoglycemia    creatinin level    overal kidney function patient ckd stage 4 vs stage 5,"renal,kidney,outcomes,creatinine,uar,scr,glomerular,gfr",Renal Outcomes (GLP1 012) (v2.0),GLP1 012,"renal , kidney , outcom , creatinin , uar , scr , glomerular , gfr",25
10,,Ozempic,SEM 120,"Can you send me any information on Ozempic’s impact on hypoglycemia, creatinine levels, and/or overall kidney function in patients with CKD stage 4 vs. stage 5?",accurate with one of docID,send inform ozemp impact hypoglycemia    creatinin level    overal kidney function patient ckd stage 4 vs stage 5,"hypoglycemia,hypo,safety",Hypoglycemia (SEM 120) (v9.0),SEM 120,"hypoglycemia , hypo , safeti",66.66666667,send inform ozemp impact hypoglycemia    creatinin level    overal kidney function patient ckd stage 4 vs stage 5,"flow,renal,kidney",The FLOW Trial (SEM 183) (v2.0),SEM 183,"flow , renal , kidney",33.33333333,send inform ozemp impact hypoglycemia    creatinin level    overal kidney function patient ckd stage 4 vs stage 5,"renal,kidney,outcomes,creatinine,uar,scr,glomerular,gfr",Renal Outcomes (GLP1 012) (v2.0),GLP1 012,"renal , kidney , outcom , creatinin , uar , scr , glomerular , gfr",25
11,REQ-43350,Wegovy,none,Would like more information on patients experiencing dramatic weight loss with wegovy.,not accurate,like inform patient eperi dramat weight loss wegovi,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25,like inform patient eperi dramat weight loss wegovi,"mtc,men 2,anti-obesity,glp-1 ras,wegovy,saxenda,aom",MTC (Medullary Thyroid Carcinoma) (GOBS 003) (v1.0),GOBS 003,"mtc , man 2,anti - obes , glp-1 ra , wegovi , saxenda , aom",14.28571429,like inform patient eperi dramat weight loss wegovi,"surmount,weight,gip,glp-1,glp1,tirzepatide,mounjaro,gip",vs tirzepatide (SEOB 063) (v3.0),SEOB 063,"surmount , weight , gip , glp-1,glp1,tirzepatid , mounjaro , gip",14.28571429
12,REQ-43424,Rybelsus,none,Provider would like to know if he can use Rybelsus on a patient that is allergic phenergan.,not accurate,provid like know use rybelsu patient allerg phenergan,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",25,provid like know use rybelsu patient allerg phenergan,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",20,provid like know use rybelsu patient allerg phenergan,"allergic,allergy,hypersensitivity,sensitivity,anaphylaxis,anaphylactic,urticaria,rash,immunogenic,immunogenicity",Allergic Reactions (OSEM 044) (v8.0),OSEM 044,"allerg , allergi , hypersensit , sensit , anaphylaxi , anaphylact , urticaria , rash , immunogen , immunogen",11.11111111
13,REQ-43498,Ozempic,SEM 125,"Please send info on Ozempic regarding GFR? Is there a GFR where Ozempic should not be used?

Would also like data on Ozempic and CHF.",not accurate,send info ozemp gfr gfr ozemp usedwould like datum ozemp chf,"heart,failure,hospitalization,chf,hf,nyha,",SUSTAIN 6-Heart Failure (SEM 163) (v7.0),SEM 163,"heart , failur , hospit , chf , hf , nyha ,",33.33333333,send info ozemp gfr gfr ozemp usedwould like datum ozemp chf,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,send info ozemp gfr gfr ozemp usedwould like datum ozemp chf,"ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,"ozemp , glucos , semaglutid , fast , fpg , preprandi",16.66666667
14,,Ozempic,SEM 163,"Please send info on Ozempic regarding GFR? Is there a GFR where Ozempic should not be used?

Would also like data on Ozempic and CHF.",accurate with one of docID,send info ozemp gfr gfr ozemp usedwould like datum ozemp chf,"heart,failure,hospitalization,chf,hf,nyha,",SUSTAIN 6-Heart Failure (SEM 163) (v7.0),SEM 163,"heart , failur , hospit , chf , hf , nyha ,",33.33333333,send info ozemp gfr gfr ozemp usedwould like datum ozemp chf,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,send info ozemp gfr gfr ozemp usedwould like datum ozemp chf,"ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,"ozemp , glucos , semaglutid , fast , fpg , preprandi",16.66666667
15,REQ-43539,Wegovy,SEOB 101,"I would normally send an MI request through Veeva but I am currently not setup in the system after moving back to the field. My role is primarily strategic project focused. .. However, I was in Washington DC this week. I was primarily with lobbyists, poli",not accurate,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,"rationale,dosing,dose,qw,week",Rationale for QW Dosing (SEOB 002) (v8.0),SEOB 002,"rational , dose , dose , qw , week",25,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,"pulse,heart,rate,bpm,beat,tachycardia,fibrillation,racing,arrhythmia",Heart Rate (SEOB 083) (v1.0),SEOB 083,"puls , heart , rate , bpm , beat , tachycardia , fibril , race , arrhythmia",11.11111111,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,excurs,0
16,,Wegovy,SEOB 102,"I would normally send an MI request through Veeva but I am currently not setup in the system after moving back to the field. My role is primarily strategic project focused. .. However, I was in Washington DC this week. I was primarily with lobbyists, poli",not accurate,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,"rationale,dosing,dose,qw,week",Rationale for QW Dosing (SEOB 002) (v8.0),SEOB 002,"rational , dose , dose , qw , week",25,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,"pulse,heart,rate,bpm,beat,tachycardia,fibrillation,racing,arrhythmia",Heart Rate (SEOB 083) (v1.0),SEOB 083,"puls , heart , rate , bpm , beat , tachycardia , fibril , race , arrhythmia",11.11111111,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,excurs,0
17,,Wegovy,SEOB 103,"I would normally send an MI request through Veeva but I am currently not setup in the system after moving back to the field. My role is primarily strategic project focused. .. However, I was in Washington DC this week. I was primarily with lobbyists, poli",not accurate,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,"rationale,dosing,dose,qw,week",Rationale for QW Dosing (SEOB 002) (v8.0),SEOB 002,"rational , dose , dose , qw , week",25,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,"pulse,heart,rate,bpm,beat,tachycardia,fibrillation,racing,arrhythmia",Heart Rate (SEOB 083) (v1.0),SEOB 083,"puls , heart , rate , bpm , beat , tachycardia , fibril , race , arrhythmia",11.11111111,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,excurs,0
18,,Wegovy,SEOB 104,"I would normally send an MI request through Veeva but I am currently not setup in the system after moving back to the field. My role is primarily strategic project focused. .. However, I was in Washington DC this week. I was primarily with lobbyists, poli",not accurate,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,"rationale,dosing,dose,qw,week",Rationale for QW Dosing (SEOB 002) (v8.0),SEOB 002,"rational , dose , dose , qw , week",25,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,"pulse,heart,rate,bpm,beat,tachycardia,fibrillation,racing,arrhythmia",Heart Rate (SEOB 083) (v1.0),SEOB 083,"puls , heart , rate , bpm , beat , tachycardia , fibril , race , arrhythmia",11.11111111,normal send mi request veeva current setup system move field role primarili strateg project focu      washington dc week primarili lobbyist    poli,excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,excurs,0
19,REQ-43546,Ozempic,SEM 007,Any reports of increased myopathy (muscle weakness) with ozempic. People with high ozempic antibody levels any correlation to increased muscle weakness. Any reports of ozempic worsening metabolic myopathy; such as Pompe disease?,accurate with one of docID,report increas myopathi    muscl weak    ozemp peopl high ozemp antibodi level correl increas muscl weak report ozemp worsen metabol myopathi    pomp diseas,"antibody,antibodies,immunogenicity",Antibodies (SEM 007) (v8.0),SEM 007,"antibodi , antibodi , immunogen",50,report increas myopathi    muscl weak    ozemp peopl high ozemp antibodi level correl increas muscl weak report ozemp worsen metabol myopathi    pomp diseas,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,report increas myopathi    muscl weak    ozemp peopl high ozemp antibodi level correl increas muscl weak report ozemp worsen metabol myopathi    pomp diseas,"ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,"ozemp , glucos , semaglutid , fast , fpg , preprandi",16.66666667
20,REQ-43551,Ozempic,SEM 178,Can I get a copy of the data that was on a slide presented at last nights at the speaker program? The slide showed the higher that hemoglobin A1c the bigger the drop with Ozempic.  I believe it was breaking out data at different patients with different A1,not accurate,copi datum slide present night speaker program slide show high hemoglobin a1c big drop ozemp    believ break datum differ patient differ a1,"sustain,overview,slide,slides,clinical",Cover to Ozempic Clinical Overview Deck (SEM 600) (v5.0),SEM 600,"sustain , overview , slide , slide , clinic",25,copi datum slide present night speaker program slide show high hemoglobin a1c big drop ozemp    believ break datum differ patient differ a1,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,copi datum slide present night speaker program slide show high hemoglobin a1c big drop ozemp    believ break datum differ patient differ a1,"clinical,overview,slide,slides,deck",Clinical Overview of Ozempic (SEM 601) (v4.0),SEM 601,"clinic , overview , slide , slide , deck",25
21,REQ-43581,Saxenda,SAX 062,Dr Udell wants to know if her patient is safe to take Saxenda if they have previously had papillary and follicular cancer,not accurate,dr udel want know patient safe saenda previous papillari follicular cancer,"cancer,tumor,oncology,neoplasm,carcinoma,breast",Breast Neoplasms (SAX 010) (v7.0),SAX 010,"cancer , tumor , oncolog , neoplasm , carcinoma , breast",16.66666667,dr udel want know patient safe saenda previous papillari follicular cancer,"pancreas,cancer,pancreatic,tumor,oncology,neoplasm,carcinoma",Pancreatic Cancer (SAX 015) (v7.0),SAX 015,"pancrea , cancer , pancreat , tumor , oncolog , neoplasm , carcinoma",14.28571429,dr udel want know patient safe saenda previous papillari follicular cancer,excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,excurs,0
22,,Saxenda,SAX 088,Dr Udell wants to know if her patient is safe to take Saxenda if they have previously had papillary and follicular cancer,not accurate,dr udel want know patient safe saenda previous papillari follicular cancer,"cancer,tumor,oncology,neoplasm,carcinoma,breast",Breast Neoplasms (SAX 010) (v7.0),SAX 010,"cancer , tumor , oncolog , neoplasm , carcinoma , breast",16.66666667,dr udel want know patient safe saenda previous papillari follicular cancer,"pancreas,cancer,pancreatic,tumor,oncology,neoplasm,carcinoma",Pancreatic Cancer (SAX 015) (v7.0),SAX 015,"pancrea , cancer , pancreat , tumor , oncolog , neoplasm , carcinoma",14.28571429,dr udel want know patient safe saenda previous papillari follicular cancer,excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,excurs,0
23,REQ-43582,Ozempic,SEM 008,"Provider has a female patient she started on ozempic. The patient took her first injection on Saturday.  On the Thursday after her first injection of ozempic .25mg, she was outside power washing. That day she noticed itchiness and swelling on her palms an",not accurate,provid femal patient start ozemp patient take inject saturday    thursday inject ozemp 25 mg    outsid power wash day notic itchi swell palm,"injections,two,0.5,escalation; split",Use of Two Concomitant Ozempic Injections (SEM 159) (v6.0),SEM 159,"inject , two,0.5,escal ; split",25,provid femal patient start ozemp patient take inject saturday    thursday inject ozemp 25 mg    outsid power wash day notic itchi swell palm,"sustain forte,forte,2,2 mg,sustain forte,forte,ozempic 2,ozempic 2 mg,ozempic 2mg,semaglutide 2mg,semaglutide 2 mg",Cover to SUSTAIN FORTE (Use of 2 mg Dose Once Weekly) (SEM 178) (v10.0),SEM 178,"sustain fort , forte,2,2 mg , sustain fort , fort , ozemp 2,ozemp 2 mg , ozemp 2 mg , semaglutid 2 mg , semaglutid 2 mg",25,provid femal patient start ozemp patient take inject saturday    thursday inject ozemp 25 mg    outsid power wash day notic itchi swell palm,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25
24,REQ-43584,Ozempic,SEM 173,"Hello. This provider is interested in how many clicks to get to the 2mg dose.
Thank you",not accurate,hello provid interest click 2 mg dosethank,"dosing,guidelines,guideline,missed dose",Dosing-Guidelines (SEM 017) (v6.0),SEM 017,"dose , guidelin , guidelin , miss dose",33.33333333,hello provid interest click 2 mg dosethank,"missed,change,missed,dose,dosing",Dosing-Missed Dose (SEM 011) (v7.0),SEM 011,"miss , chang , miss , dose , dose",33.33333333,hello provid interest click 2 mg dosethank,"doses,greater,max,dose,forte,2 mg,sustain forte",Doses Greater Than 1 mg (SEM 170) (v6.0),SEM 170,"dose , great , max , dose , forte,2 mg , sustain fort",33.33333333
25,REQ-43590,Rybelsus,none,Can you lower the dose of metformin when you start a patient on Rybelsus?  Is there any data around this question that can be provided?,not accurate,low dose metformin start patient rybelsu    datum question provid,"exercise,dosing,physical activity",Dosing-Impact of Exercise (OSEM 091) (v6.0),OSEM 091,"exercis , dose , physic activ",33.33333333,low dose metformin start patient rybelsu    datum question provid,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",25,low dose metformin start patient rybelsu    datum question provid,"3 mg,initiation,starting,starter",3 mg Safety and Efficacy (OSEM 053) (v12.0),OSEM 053,"3 mg , initi , start , starter",25
26,REQ-43598,Ozempic,SEM 125,Ms penson asked for any on going study information with ozempic and the kidneys,not accurate,ms penson ask go studi inform ozemp kidney,"flow,renal,kidney",The FLOW Trial (SEM 183) (v2.0),SEM 183,"flow , renal , kidney",33.33333333,ms penson ask go studi inform ozemp kidney,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,ms penson ask go studi inform ozemp kidney,"ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,"ozemp , glucos , semaglutid , fast , fpg , preprandi",16.66666667
27,,Ozempic,SEM 126,Ms penson asked for any on going study information with ozempic and the kidneys,not accurate,ms penson ask go studi inform ozemp kidney,"flow,renal,kidney",The FLOW Trial (SEM 183) (v2.0),SEM 183,"flow , renal , kidney",33.33333333,ms penson ask go studi inform ozemp kidney,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,ms penson ask go studi inform ozemp kidney,"ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,"ozemp , glucos , semaglutid , fast , fpg , preprandi",16.66666667
28,REQ-43599,Saxenda,SEOB 049,What are the recommendations of switching patients from Saxenda to Wegovy.  Which wegovy dose is compatible/COMPARABLE  to Saxenda 3mg dose,not accurate,recommend switch patient saenda wegovi    wegovi dose compat compar    saenda 3 mg dose,"switching,switch,wegovy,semaglutide",Switching from GLP-1 RAs (SAX 102) (v5.0),SAX 102,"switch , switch , wegovi , semaglutid",66.66666667,recommend switch patient saenda wegovi    wegovi dose compat compar    saenda 3 mg dose,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25,recommend switch patient saenda wegovi    wegovi dose compat compar    saenda 3 mg dose,"mtc,men 2,anti-obesity,glp-1 ras,wegovy,saxenda,aom",MTC (Medullary Thyroid Carcinoma) (GOBS 003) (v1.0),GOBS 003,"mtc , man 2,anti - obes , glp-1 ra , wegovi , saxenda , aom",14.28571429
29,REQ-43600,Ozempic,SEM 124,How do you transition a patient from Victoza to Ozempic?,not accurate,transit patient victoza ozemp,"weight,victoza",Weight vs. Victoza (SEM 142) (v6.0),SEM 142,"weight , victoza",50,transit patient victoza ozemp,"structure,victoza",Structure vs Victoza  (SEM 129) (v6.0),SEM 129,"structur , victoza",50,transit patient victoza ozemp,"victoza,liraglutide,sustain 10",vs Victoza (SEM 116) (v11.0),SEM 116,"victoza , liraglutid , sustain 10",33.33333333
30,REQ-43601,Wegovy,SEOB 105,Customer requested links to Wegovy phase3b STEP trials.,not accurate,custom request link wegovi phase3b step trial,step,Media-STEP 1 Video (SEOB 3001) (v1.0),SEOB 3001,step,100,custom request link wegovi phase3b step trial,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25,custom request link wegovi phase3b step trial,"step,sustain,forte,diabetes,t2d",STEP 2 vs SUSTAIN FORTE (SEOB 057) (v1.0),SEOB 057,"step , sustain , fort , diabet , t2d",20
31,,Wegovy,SEOB 108,Customer requested links to Wegovy phase3b STEP trials.,not accurate,custom request link wegovi phase3b step trial,step,Media-STEP 1 Video (SEOB 3001) (v1.0),SEOB 3001,step,100,custom request link wegovi phase3b step trial,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25,custom request link wegovi phase3b step trial,"step,sustain,forte,diabetes,t2d",STEP 2 vs SUSTAIN FORTE (SEOB 057) (v1.0),SEOB 057,"step , sustain , fort , diabet , t2d",20
32,,Wegovy,SEOB 113,Customer requested links to Wegovy phase3b STEP trials.,not accurate,custom request link wegovi phase3b step trial,step,Media-STEP 1 Video (SEOB 3001) (v1.0),SEOB 3001,step,100,custom request link wegovi phase3b step trial,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25,custom request link wegovi phase3b step trial,"step,sustain,forte,diabetes,t2d",STEP 2 vs SUSTAIN FORTE (SEOB 057) (v1.0),SEOB 057,"step , sustain , fort , diabet , t2d",20
33,REQ-43603,Ozempic,SEM 154,"Dr. Hart wants to know if there are any studies concerning prescribing Rybelsus or Ozempic for patients who have had gastric bypass surgery. If no studies, can you give any information for this type of patient.",accurate with one of docID,dr hart want know studi concern prescrib rybelsu ozemp patient gastric bypass surgeri studi    inform type patient,"bariatric,gastric,bypass,sleeve,surgery",Bariatric Surgery (SEM 154) (v6.0),SEM 154,"bariatr , gastric , bypass , sleev , surgeri",60,dr hart want know studi concern prescrib rybelsu ozemp patient gastric bypass surgeri studi    inform type patient,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,dr hart want know studi concern prescrib rybelsu ozemp patient gastric bypass surgeri studi    inform type patient,"surgery,operation,pre-op,npo,procedure,anesthesia",Surgery (SEM 160) (v4.0),SEM 160,"surgeri , oper , pre - op , npo , procedur , anesthesia",16.66666667
34,,Ozempic,OSEM 092,"Dr. Hart wants to know if there are any studies concerning prescribing Rybelsus or Ozempic for patients who have had gastric bypass surgery. If no studies, can you give any information for this type of patient.",not accurate,dr hart want know studi concern prescrib rybelsu ozemp patient gastric bypass surgeri studi    inform type patient,"bariatric,gastric,bypass,sleeve,surgery",Bariatric Surgery (SEM 154) (v6.0),SEM 154,"bariatr , gastric , bypass , sleev , surgeri",60,dr hart want know studi concern prescrib rybelsu ozemp patient gastric bypass surgeri studi    inform type patient,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,dr hart want know studi concern prescrib rybelsu ozemp patient gastric bypass surgeri studi    inform type patient,"surgery,operation,pre-op,npo,procedure,anesthesia",Surgery (SEM 160) (v4.0),SEM 160,"surgeri , oper , pre - op , npo , procedur , anesthesia",16.66666667
35,REQ-43605,Ozempic,SEM 125,"Patient with egfr of 12, can I put her on Ozempic?  Patient has type 2.  And on dialysis.",accurate with one of docID,patient egfr 12    ozemp    patient type 2    dialysi,"renal,kidney,dialysis,esrd,gfr,egfr,creatinine,clearance,crcl,nephrotic,transplant",Renal Impairment (SEM 125) (v13.0),SEM 125,"renal , kidney , dialysi , esrd , gfr , egfr , creatinin , clearanc , crcl , nephrot , transplant",27.27272727,patient egfr 12    ozemp    patient type 2    dialysi,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,patient egfr 12    ozemp    patient type 2    dialysi,"ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,"ozemp , glucos , semaglutid , fast , fpg , preprandi",16.66666667
36,REQ-43607,Ozempic,SEM 012,Dr. Nosser wanted information about if a patient who had thyroid cancer and had their thyroid removed was eligible for Ozempic.,not accurate,dr nosser want inform patient thyroid cancer thyroid remov elig ozemp,"neoplasms,cancer,neoplasm",Neoplasms  (SEM 134) (v7.0),SEM 134,"neoplasm , cancer , neoplasm",50,dr nosser want inform patient thyroid cancer thyroid remov elig ozemp,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,dr nosser want inform patient thyroid cancer thyroid remov elig ozemp,"pancreatic,cancer,neoplasm,neoplasms,pancreas,pancreatic cancer",Pancreatic Cancer (SEM 032) (v9.0),SEM 032,"pancreat , cancer , neoplasm , neoplasm , pancrea , pancreat cancer",20
37,REQ-43608,Saxenda,SAX 062,“What if they had thyroid cancer but it is not medullary?,not accurate,thyroid cancer medullari,"thyroid,thyroid neoplasms,mtc,men 2,calcitonin",Thyroid Neoplasms (SAX 018) (v1.0),SAX 018,"thyroid , thyroid neoplasm , mtc , man 2,calcitonin",20,thyroid cancer medullari,"cancer,tumor,oncology,neoplasm,carcinoma,breast",Breast Neoplasms (SAX 010) (v7.0),SAX 010,"cancer , tumor , oncolog , neoplasm , carcinoma , breast",16.66666667,thyroid cancer medullari,"pancreas,cancer,pancreatic,tumor,oncology,neoplasm,carcinoma",Pancreatic Cancer (SAX 015) (v7.0),SAX 015,"pancrea , cancer , pancreat , tumor , oncolog , neoplasm , carcinoma",14.28571429
38,REQ-43610,Wegovy,SEOB 049,"Please e-mail HCP the following Med Info letter:
- SEOB 049 - Switching from Saxenda",accurate with one of docID,email hcp follow med info letter seob 049    switch saenda,"ozempic,switch,transition",Switching from Ozempic (SEOB 065) (v7.0),SEOB 065,"ozemp , switch , transit",33.33333333,email hcp follow med info letter seob 049    switch saenda,"switch,transition,saxenda,liraglutide",Switching from Saxenda (SEOB 049) (v6.0),SEOB 049,"switch , transit , saxenda , liraglutid",25,email hcp follow med info letter seob 049    switch saenda,"rybelsus,switch,transition,tablets,oral",Switching from Rybelsus (SEOB 118) (v2.0),SEOB 118,"rybelsu , switch , transit , tablet , oral",20
39,REQ-43612,Rybelsus,OSEM 005,All information on Rybelsus cv data and studies,not accurate,inform rybelsu cv datum studi,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",40,inform rybelsu cv datum studi,"soul,cardiovascular outcomes,cv,ongoing",Rybelsus and the SOUL Trial (OSEM 139) (v2.0),OSEM 139,"soul , cardiovascular outcom , cv , ongo",25,inform rybelsu cv datum studi,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",25
40,REQ-43613,Rybelsus,OSEM 069,Any information on Rybelsus and glp1’s and heartburn,not accurate,inform rybelsu glp1 heartburn,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",25,inform rybelsu glp1 heartburn,"approval,overview,glp-1,glp1",Approval and Product Overview (OSEM 010) (v12.0),OSEM 010,"approv , overview , glp-1,glp1",25,inform rybelsu glp1 heartburn,"pioneer,pioneer 1,monotherapy,placebo,p1",Media-PIONEER 1 Video (OSEM 3001) (v2.0),OSEM 3001,"pioneer , pioneer 1,monotherapi , placebo , p1",20
41,REQ-43615,Wegovy,SEOB 122,Patient started on wegovy .25 now needs the .5 pen which is not available. 1.0 pen is. Is there a way to adjust 1.0 pen to give .5? Or just try to increase to 1.0 Pt says insurance won’t cover ozempic as alternative,not accurate,patient start wegovi 25 need 5 pen avail 10 pen way adjust 10 pen 5 tri increas 10 pt say insur will not cover ozemp altern,"ozempic,versus,vs",vs Ozempic (SEOB 026) (v5.0),SEOB 026,"ozemp , versu , vs",33.33333333,patient start wegovi 25 need 5 pen avail 10 pen way adjust 10 pen 5 tri increas 10 pt say insur will not cover ozemp altern,"ozempic,switch,transition",Switching from Ozempic (SEOB 065) (v7.0),SEOB 065,"ozemp , switch , transit",33.33333333,patient start wegovi 25 need 5 pen avail 10 pen way adjust 10 pen 5 tri increas 10 pt say insur will not cover ozemp altern,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25
42,REQ-43626,Norditropin,GHC 002,"Please email this info to the pharmacy: If unopened Norditropin® FlexPro® was left at room temperature (up to 77°F), it must be used within 3 weeks from the day it was left out. Unused portion should be discarded. Do not use past expiration date.Dr. OSCAR",not accurate,email info pharmaci unopen norditropin flepro left room temperatur    77f     3 week day leav unus portion discard use past epir datedr oscar,"product information,pi,package insert",PI Discussion (Verbal Response Only) (GEN 1001) (v2.0),GEN 1001,"product inform , pi , packag insert",33.33333333,email info pharmaci unopen norditropin flepro left room temperatur    77f     3 week day leav unus portion discard use past epir datedr oscar,"amcp,dossier,4 pg,norditropin",Norditropin Medicaid Summary-4 page (GHC 401) (v4.0),GHC 401,"amcp , dossier,4 pg , norditropin",25,email info pharmaci unopen norditropin flepro left room temperatur    77f     3 week day leav unus portion discard use past epir datedr oscar,"amcp,summary,dossier,norditropin",Norditropin Medicaid Summary - 1 page (GHC 400) (v4.0),GHC 400,"amcp , summari , dossier , norditropin",25
43,REQ-43631,Rybelsus,OSEM 139,Asked to see information from the Rybelsus SOUL trial,accurate with one of docID,ask inform rybelsu soul trial,"soul,cardiovascular outcomes,cv,ongoing",Rybelsus and the SOUL Trial (OSEM 139) (v2.0),OSEM 139,"soul , cardiovascular outcom , cv , ongo",25,ask inform rybelsu soul trial,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",25,ask inform rybelsu soul trial,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",20
44,REQ-43632,Rybelsus,SEOB 025,Are there any additional trials/data for weight management and Rybelsus used in the diabetes and/or obesity market.  Will Rybelsus have an indication for weight management?,not accurate,addit trial datum weight manag rybelsu diabet obes market    rybelsu indic weight manag,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",40,addit trial datum weight manag rybelsu diabet obes market    rybelsu indic weight manag,"ddi,di,interaction,levothyroxine,thyroid,omeprazole,ppi",Media-Drug Interactions Video (OSEM 3009) (v2.0),OSEM 3009,"ddi , di , interact , levothyroxin , thyroid , omeprazol , ppi",28.57142857,addit trial datum weight manag rybelsu diabet obes market    rybelsu indic weight manag,"gastrointestinal,gi,management,ae",Management of GI Adverse Events (GLP1 014) (v1.0),GLP1 014,"gastrointestin , gi , manag , ae",25
45,REQ-43634,Ozempic,SEM 105,Please send SUSTAIN 5 (SEM 105) per conversation on Ozempic add-on to basal insulin,accurate with one of docID,send sustain 5    sem 105    convers ozemp addon basal insulin,"basal,insulin,glargine,lantus",vs Basal insulin (SEM 113) (v7.0),SEM 113,"basal , insulin , glargin , lantu",50,send sustain 5    sem 105    convers ozemp addon basal insulin,"sustain,sglt-2,sglt2,add,sustain 9,sustain 9",Cover to SUSTAIN 9 (add-on SGLT-2i) (SEM 109) (v5.0),SEM 109,"sustain , sglt-2,sglt2,add , sustain 9,sustain 9",40,send sustain 5    sem 105    convers ozemp addon basal insulin,"sustain,insulin,basal,glargine,degludec,lantus,tresiba,nph",Cover to SUSTAIN 5 (add on to basal insulin) (SEM 105) (v6.0),SEM 105,"sustain , insulin , basal , glargin , degludec , lantu , tresiba , nph",37.5
46,REQ-43635,Ozempic,SEM 004,Is there an ongoing study monitoring retinopathy. Were there patients that could not complete the study because of retinopathy.,accurate with one of docID,ongo studi monitor retinopathi patient complet studi retinopathi,"retinopathy,eye,drc,diabetic retinopathy complications,diabetic retinopathy,blindness,blind,vitreous hemorrhage,retina,visual,microvascular",Retinopathy (SEM 004) (v16.0),SEM 004,"retinopathi , eye , drc , diabet retinopathi complic , diabet retinopathi , blind , blind , vitreou hemorrhag , retina , visual , microvascular",10,ongo studi monitor retinopathi patient complet studi retinopathi,excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,excurs,0,ongo studi monitor retinopathi patient complet studi retinopathi,"niosh,hazardous",NIOSH Classification (Sema) (SEM 300) (v6.0),SEM 300,"niosh , hazard",0
47,REQ-43638,Ozempic,SEM 139,Can Ozempic be used in patients with liver impairment including cirrhosis of the liver?,accurate with one of docID,ozemp patient liver impair includ cirrhosi liver,"hepatic,liver,impairment,ast,alt,alanine aminotransferase,aspartate aminotransferase,hepatic enzymes",Hepatic Function and Impairment (SEM 139) (v8.0),SEM 139,"hepat , liver , impair , ast , alt , alanin aminotransferas , aspart aminotransferas , hepat enzym",25,ozemp patient liver impair includ cirrhosi liver,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,ozemp patient liver impair includ cirrhosi liver,"ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,"ozemp , glucos , semaglutid , fast , fpg , preprandi",16.66666667
48,REQ-43640,Wegovy,SEOB 043,HCP has questions about the use of semaglutide in a patient on dialysis (PD) with a high insulin requirement.  Please send appropriate information if available,not accurate,hcp question use semaglutid patient dialysi    pd    high insulin requir    send appropri inform avail,"t1d,type 1,insulin",Type 1 Diabetes (SEOB 054) (v1.0),SEOB 054,"t1d , type 1,insulin",33.33333333,hcp question use semaglutid patient dialysi    pd    high insulin requir    send appropri inform avail,"interaction,ddi,di,oral,hypoglycemia,insulin,sulfonylurea,secretagogue",Drug Interactions (SEOB 012) (v5.0),SEOB 012,"interact , ddi , di , oral , hypoglycemia , insulin , sulfonylurea , secretagogu",25,hcp question use semaglutid patient dialysi    pd    high insulin requir    send appropri inform avail,"pharmacokinetics,pharmacodynamics,pk,pd",PK-PD (SEOB 076) (v1.0),SEOB 076,"pharmacokinet , pharmacodynam , pk , pd",25
49,REQ-43648,Rybelsus,OSEM 112,Physician asking how to administer Rybelsus in a patient who needs to take thyroid medication too.,not accurate,physician ask administ rybelsu patient need thyroid medic,"ddi,di,interaction,levothyroxine,thyroid,omeprazole,ppi",Media-Drug Interactions Video (OSEM 3009) (v2.0),OSEM 3009,"ddi , di , interact , levothyroxin , thyroid , omeprazol , ppi",28.57142857,physician ask administ rybelsu patient need thyroid medic,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",25,physician ask administ rybelsu patient need thyroid medic,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",20
50,REQ-43649,Rybelsus,OSEM 040,How do nausea rates compare between ozempic and rybelsus (please include MI letter OSEM 040 in response,not accurate,nausea rate compar ozemp rybelsu    includ mi letter osem 040 respons,"nausea,nauseous",Nausea (OSEM 075) (v9.0),OSEM 075,"nausea , nauseou",50,nausea rate compar ozemp rybelsu    includ mi letter osem 040 respons,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",50,nausea rate compar ozemp rybelsu    includ mi letter osem 040 respons,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",40
51,REQ-43650,Saxenda,SEOB 047,This is for saxenda and wegovy - dr wants to know what information we have to share on treating NASH with our products she has a lot of pts with NASH and she has read about GLP-1 use in those pts,not accurate,saenda wegovi    dr want know inform share treat nash product lot pt nash read glp1 use pt,"switching,switch,wegovy,semaglutide",Switching from GLP-1 RAs (SAX 102) (v5.0),SAX 102,"switch , switch , wegovi , semaglutid",33.33333333,saenda wegovi    dr want know inform share treat nash product lot pt nash read glp1 use pt,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25,saenda wegovi    dr want know inform share treat nash product lot pt nash read glp1 use pt,"summary,overview,information,monograph",Product Overview (SAX 025) (v7.0),SAX 025,"summari , overview , inform , monograph",25
52,,Saxenda,SAX 042,This is for saxenda and wegovy - dr wants to know what information we have to share on treating NASH with our products she has a lot of pts with NASH and she has read about GLP-1 use in those pts,not accurate,saenda wegovi    dr want know inform share treat nash product lot pt nash read glp1 use pt,"switching,switch,wegovy,semaglutide",Switching from GLP-1 RAs (SAX 102) (v5.0),SAX 102,"switch , switch , wegovi , semaglutid",33.33333333,saenda wegovi    dr want know inform share treat nash product lot pt nash read glp1 use pt,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25,saenda wegovi    dr want know inform share treat nash product lot pt nash read glp1 use pt,"summary,overview,information,monograph",Product Overview (SAX 025) (v7.0),SAX 025,"summari , overview , inform , monograph",25
53,REQ-43651,Wegovy,SAX 012,"What are the long term side effects of chronic GLP1RA use, specifically on the pancreas/metabolically?",not accurate,long term effect chronic glp1ra use    specif pancrea metabol,"long-term,longest,duration,longer,long,step 5",Long-Term Data (SEOB 088) (v3.0),SEOB 088,"long - term , long , durat , long , long , step 5",25,long term effect chronic glp1ra use    specif pancrea metabol,"cancer,neoplasm,pancreas,pancreatic",Pancreatic Cancer (SEOB 021) (v4.0),SEOB 021,"cancer , neoplasm , pancrea , pancreat",25,long term effect chronic glp1ra use    specif pancrea metabol,"adverse,adverse event,common,adverse reaction,side effect",Adverse Reactions-Clinical Trials (SEOB 064) (v2.0),SEOB 064,"advers , advers event , common , advers reaction , effect",20
54,,Wegovy,SAX 013,"What are the long term side effects of chronic GLP1RA use, specifically on the pancreas/metabolically?",not accurate,long term effect chronic glp1ra use    specif pancrea metabol,"long-term,longest,duration,longer,long,step 5",Long-Term Data (SEOB 088) (v3.0),SEOB 088,"long - term , long , durat , long , long , step 5",25,long term effect chronic glp1ra use    specif pancrea metabol,"cancer,neoplasm,pancreas,pancreatic",Pancreatic Cancer (SEOB 021) (v4.0),SEOB 021,"cancer , neoplasm , pancrea , pancreat",25,long term effect chronic glp1ra use    specif pancrea metabol,"adverse,adverse event,common,adverse reaction,side effect",Adverse Reactions-Clinical Trials (SEOB 064) (v2.0),SEOB 064,"advers , advers event , common , advers reaction , effect",20
55,REQ-43652,Ozempic,SEM 091,Are there any studies using Ozempic with Type1 and Type 1.5 Diabetics?,not accurate,studi ozemp type1 type 15 diabet,"type 1,diabetes,t1dm,t1d",Type 1 Diabetes (SEM 090) (v12.0),SEM 090,"type 1,diabet , t1 dm , t1d",50,studi ozemp type1 type 15 diabet,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,studi ozemp type1 type 15 diabet,"type 1 diabetes mellitus,type 1 diabetes,type 1,t1d,t1dm",Type 1 Diabetes (GLP1 008) (v3.0),GLP1 008,"type 1 diabet mellitu , type 1 diabet , type 1,t1d , t1 dm",20
56,,Ozempic,SEM 090,Are there any studies using Ozempic with Type1 and Type 1.5 Diabetics?,accurate with one of docID,studi ozemp type1 type 15 diabet,"type 1,diabetes,t1dm,t1d",Type 1 Diabetes (SEM 090) (v12.0),SEM 090,"type 1,diabet , t1 dm , t1d",50,studi ozemp type1 type 15 diabet,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,studi ozemp type1 type 15 diabet,"type 1 diabetes mellitus,type 1 diabetes,type 1,t1d,t1dm",Type 1 Diabetes (GLP1 008) (v3.0),GLP1 008,"type 1 diabet mellitu , type 1 diabet , type 1,t1d , t1 dm",20
57,REQ-43654,Wegovy,SAX 051,This is for saxenda and wegovy - dr is asking for what is the long term data for both saxenda and wegovy as far as pts maintaining therapy and what is the results of patients coming off therapy and how much weight did those pts regain once coming off ther,not accurate,saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain come ther,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25,saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain come ther,"long-term,longest,duration,longer,long,step 5",Long-Term Data (SEOB 088) (v3.0),SEOB 088,"long - term , long , durat , long , long , step 5",25,saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain come ther,"step,overview,slide,clinical,pi",Clinical Overview of Wegovy (SEOB 601) (v1.0),SEOB 601,"step , overview , slide , clinic , pi",20
58,,Wegovy,SEOB 042,This is for saxenda and wegovy - dr is asking for what is the long term data for both saxenda and wegovy as far as pts maintaining therapy and what is the results of patients coming off therapy and how much weight did those pts regain once coming off ther,not accurate,saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain come ther,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25,saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain come ther,"long-term,longest,duration,longer,long,step 5",Long-Term Data (SEOB 088) (v3.0),SEOB 088,"long - term , long , durat , long , long , step 5",25,saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain come ther,"step,overview,slide,clinical,pi",Clinical Overview of Wegovy (SEOB 601) (v1.0),SEOB 601,"step , overview , slide , clinic , pi",20
59,,Wegovy,SEOB 088,This is for saxenda and wegovy - dr is asking for what is the long term data for both saxenda and wegovy as far as pts maintaining therapy and what is the results of patients coming off therapy and how much weight did those pts regain once coming off ther,accurate with one of docID,saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain come ther,"bariatric surgery,anti-obesity medications,saxenda,wegovy",Bariatric Surgery (GOBS 001) (v1.0),GOBS 001,"bariatr surgeri , anti - obes medic , saxenda , wegovi",25,saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain come ther,"long-term,longest,duration,longer,long,step 5",Long-Term Data (SEOB 088) (v3.0),SEOB 088,"long - term , long , durat , long , long , step 5",25,saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain come ther,"step,overview,slide,clinical,pi",Clinical Overview of Wegovy (SEOB 601) (v1.0),SEOB 601,"step , overview , slide , clinic , pi",20
60,REQ-43655,Saxenda,SAX 047,What is the pediatric data for Saxenda? Would like to see studies,accurate with one of docID,pediatr datum saenda like studi,"pediatrics,teens,adolescents,children,pediatric",Pediatrics (SAX 047) (v9.0),SAX 047,"pediatr , teen , adolesc , child , pediatr",25,pediatr datum saenda like studi,excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,excurs,0,pediatr datum saenda like studi,"niosh,hazardous",NIOSH Classification (Lira) (GLP1 300) (v6.0),GLP1 300,"niosh , hazard",0
61,REQ-43658,Ozempic,SEM 105,"Is there data that can be emailed to help support prescribing Ozempic for a patient with type 2 diabetes where the patient had an inadequate A1C response with Metformin and insulin. Also, the patient has a family history of cardiovascular disease.",not accurate,datum email help support prescrib ozemp patient type 2 diabet patient inadequ a1c respons metformin insulin    patient famili histori cardiovascular diseas,"cv,cardiovascular",SUSTAIN 6-CV Outcomes in Subgroup of Patients with CV Risk Factors (SEM 165) (v3.0),SEM 165,"cv , cardiovascular",50,datum email help support prescrib ozemp patient type 2 diabet patient inadequ a1c respons metformin insulin    patient famili histori cardiovascular diseas,"kapitza,beta,insulin,response",Cover to Kapitza et al. (Insulin Response) (SEM 151) (v5.0),SEM 151,"kapitza , beta , insulin , respons",50,datum email help support prescrib ozemp patient type 2 diabet patient inadequ a1c respons metformin insulin    patient famili histori cardiovascular diseas,"cardiovascular,indication,cv",CV Indication (SEM 153) (v6.0),SEM 153,"cardiovascular , indic , cv",33.33333333
62,,Ozempic,SEM 106,"Is there data that can be emailed to help support prescribing Ozempic for a patient with type 2 diabetes where the patient had an inadequate A1C response with Metformin and insulin. Also, the patient has a family history of cardiovascular disease.",not accurate,datum email help support prescrib ozemp patient type 2 diabet patient inadequ a1c respons metformin insulin    patient famili histori cardiovascular diseas,"cv,cardiovascular",SUSTAIN 6-CV Outcomes in Subgroup of Patients with CV Risk Factors (SEM 165) (v3.0),SEM 165,"cv , cardiovascular",50,datum email help support prescrib ozemp patient type 2 diabet patient inadequ a1c respons metformin insulin    patient famili histori cardiovascular diseas,"kapitza,beta,insulin,response",Cover to Kapitza et al. (Insulin Response) (SEM 151) (v5.0),SEM 151,"kapitza , beta , insulin , respons",50,datum email help support prescrib ozemp patient type 2 diabet patient inadequ a1c respons metformin insulin    patient famili histori cardiovascular diseas,"cardiovascular,indication,cv",CV Indication (SEM 153) (v6.0),SEM 153,"cardiovascular , indic , cv",33.33333333
63,REQ-43659,Ozempic,SEM 124,"Dr Castaneda would like more information on converting a patient from Rybelsus to Ozempic? Is these a dose equivalency when switching a patient from a maintenance dose (7 or 14mg)  of Rybelsus to Ozempic (.25, .5, or 1mg)?",accurate with one of docID,dr castaneda like inform convert patient rybelsu ozemp dose equival switch patient mainten dose    7 14 mg     rybelsu ozemp    25    5    1 mg,"switching,switch,convert,converting,conversion,transition,transitioning,switches,converts,transitions,",Switching from GLP-1 (SEM 124) (v10.0),SEM 124,"switch , switch , convert , convert , convers , transit , transit , switch , convert , transit ,",50,dr castaneda like inform convert patient rybelsu ozemp dose equival switch patient mainten dose    7 14 mg     rybelsu ozemp    25    5    1 mg,"dosing,guidelines,guideline,missed dose",Dosing-Guidelines (SEM 017) (v6.0),SEM 017,"dose , guidelin , guidelin , miss dose",33.33333333,dr castaneda like inform convert patient rybelsu ozemp dose equival switch patient mainten dose    7 14 mg     rybelsu ozemp    25    5    1 mg,"missed,change,missed,dose,dosing",Dosing-Missed Dose (SEM 011) (v7.0),SEM 011,"miss , chang , miss , dose , dose",33.33333333
64,REQ-43661,Saxenda,SEOB 009,"What is Novo currently studying for pediatric patients living with obesity or experiencing weight gain? Provider sees a need, especially with adolescents on antipsychotic medications.",not accurate,novo current studi pediatr patient live obes eperi weight gain provid see need    especi adolesc antipsychot medic,"adolescent,adolescents,teens",Adolescents with Obesity (SCALE TEENS) (SAX 103) (v2.0),SAX 103,"adolesc , adolesc , teen",50,novo current studi pediatr patient live obes eperi weight gain provid see need    especi adolesc antipsychot medic,"efficacy,weight,",Weight (SAX 004) (v6.0),SAX 004,"efficaci , weight ,",50,novo current studi pediatr patient live obes eperi weight gain provid see need    especi adolesc antipsychot medic,"pediatrics,teens,adolescents,children,pediatric",Pediatrics (SAX 047) (v9.0),SAX 047,"pediatr , teen , adolesc , child , pediatr",50
65,REQ-43662,Saxenda,SAX 061,Inquiry Text: This is for saxenda and wegovy - dr is asking for what is the long term data for both saxenda and wegovy as far as pts maintaining therapy and what is the results of patients coming off therapy and how much weight did those pts regain once c,not accurate,inquiri tet saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain c,regain,Weight Regain After Discontinuation (SAX 051) (v5.0),SAX 051,regain,100,inquiri tet saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain c,"efficacy,weight,",Weight (SAX 004) (v6.0),SAX 004,"efficaci , weight ,",50,inquiri tet saenda wegovi    dr ask long term datum saenda wegovi far pt maintain therapi result patient come therapi weight pt regain c,"switching,switch,wegovy,semaglutide",Switching from GLP-1 RAs (SAX 102) (v5.0),SAX 102,"switch , switch , wegovi , semaglutid",33.33333333
66,REQ-43671,Rybelsus,OSEM 021,Doctor requested any additional information on whether Rybelsus is safe in patients with diminished egfr of less then 30.,not accurate,doctor request addit inform rybelsu safe patient diminish egfr 30,"ddi,di,interaction,levothyroxine,thyroid,omeprazole,ppi",Media-Drug Interactions Video (OSEM 3009) (v2.0),OSEM 3009,"ddi , di , interact , levothyroxin , thyroid , omeprazol , ppi",28.57142857,doctor request addit inform rybelsu safe patient diminish egfr 30,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",25,doctor request addit inform rybelsu safe patient diminish egfr 30,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",20
67,REQ-43672,Ozempic,SEM 004,HCP would like more information and data within clinical trials regarding diabetic retinopathy with Ozempic,not accurate,hcp like inform datum clinic trial diabet retinopathi ozemp,"sustain,phase,trials,trial,clinical,overview",SUSTAIN Overview (All Phase 3) (SEM 111) (v10.0),SEM 111,"sustain , phase , trial , trial , clinic , overview",40,hcp like inform datum clinic trial diabet retinopathi ozemp,"type 1,diabetes,t1dm,t1d",Type 1 Diabetes (SEM 090) (v12.0),SEM 090,"type 1,diabet , t1 dm , t1d",25,hcp like inform datum clinic trial diabet retinopathi ozemp,"sustain,overview,slide,slides,clinical",Cover to Ozempic Clinical Overview Deck (SEM 600) (v5.0),SEM 600,"sustain , overview , slide , slide , clinic",25
68,REQ-43680,Ozempic,SEM 164,How does the MOA of Ozempic create a CV benefit? She has looked at the studies and can see how an SGL2 creates a CV benefit but doesn’t understand how Ozempic does.,not accurate,moa ozemp creat cv benefit look studi sgl2 creat cv benefit not understand ozemp,"cv,cardiovascular",SUSTAIN 6-CV Outcomes in Subgroup of Patients with CV Risk Factors (SEM 165) (v3.0),SEM 165,"cv , cardiovascular",50,moa ozemp creat cv benefit look studi sgl2 creat cv benefit not understand ozemp,"cardiovascular,indication,cv",CV Indication (SEM 153) (v6.0),SEM 153,"cardiovascular , indic , cv",33.33333333,moa ozemp creat cv benefit look studi sgl2 creat cv benefit not understand ozemp,"cv,cv indication,cv risk reduction,cardiovascular",Rationale for CV Indication (SEM 162) (v3.0),SEM 162,"cv , cv indic , cv risk reduct , cardiovascular",25
69,REQ-43682,Ozempic,SEM 027,Pharm D asked if we have any data for Ozempic being used with patients with kidney transplant? Looking for safety and efficiency data if we have any.,accurate with one of docID,pharm d ask datum ozemp patient kidney transplant look safeti effici datum,"transplant,solid organ transplant,kidney transplant,liver transplant",Transplant (SEM 027) (v5.0),SEM 027,"transplant , solid organ transplant , kidney transplant , liver transplant",50,pharm d ask datum ozemp patient kidney transplant look safeti effici datum,"hypoglycemia,hypo,safety",Hypoglycemia (SEM 120) (v9.0),SEM 120,"hypoglycemia , hypo , safeti",33.33333333,pharm d ask datum ozemp patient kidney transplant look safeti effici datum,"flow,renal,kidney",The FLOW Trial (SEM 183) (v2.0),SEM 183,"flow , renal , kidney",33.33333333
70,REQ-43683,General-Obesity,SEOB 069,"Provider wants to know if novo needles contain nickel for patient that has nickel allergy 

Also, wants information on GLP-1 and gastroparesis in the setting of post gastric bypass in the setting of weight regain",not accurate,,,,,,,,,,,,,,,,,,
71,,General-Obesity,SAX 054,"Provider wants to know if novo needles contain nickel for patient that has nickel allergy 

Also, wants information on GLP-1 and gastroparesis in the setting of post gastric bypass in the setting of weight regain",not accurate,,,,,,,,,,,,,,,,,,
72,,General-Obesity,SAX 090,"Provider wants to know if novo needles contain nickel for patient that has nickel allergy 

Also, wants information on GLP-1 and gastroparesis in the setting of post gastric bypass in the setting of weight regain",not accurate,,,,,,,,,,,,,,,,,,
73,REQ-43684,Rybelsus,OSEM 120,Provider requested information on  Rybelsus  and the cardio benefits it may offer in the geriatric patients population.  Also were there any additional side effects seen in the geriatric population vs the younger population.,not accurate,provid request inform    rybelsu    cardio benefit offer geriatr patient popul    addit effect see geriatr popul vs young popul,"ddi,di,interaction,levothyroxine,thyroid,omeprazole,ppi",Media-Drug Interactions Video (OSEM 3009) (v2.0),OSEM 3009,"ddi , di , interact , levothyroxin , thyroid , omeprazol , ppi",28.57142857,provid request inform    rybelsu    cardio benefit offer geriatr patient popul    addit effect see geriatr popul vs young popul,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",25,provid request inform    rybelsu    cardio benefit offer geriatr patient popul    addit effect see geriatr popul vs young popul,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",20
74,REQ-43685,Ozempic,SEM 125,Physician is wanting information on using Ozempic in a patient on dialysis.,not accurate,physician want inform ozemp patient dialysi,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25,physician want inform ozemp patient dialysi,"ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,"ozemp , glucos , semaglutid , fast , fpg , preprandi",16.66666667,physician want inform ozemp patient dialysi,"click,clicks,unmarked dosing,pen,marked,unmarked,increment,dosing,dial,dose,doses",Pen-Dosing by Clicks (SEM 173) (v4.0),SEM 173,"click , click , unmark dose , pen , mark , unmark , increment , dose , dial , dose , dose",12.5
75,REQ-43686,Wegovy,SEOB 026,Please provide clinical differences between Ozempic and Wygovy,accurate with one of docID,provid clinic differ ozemp wygovi,"ozempic,versus,vs",vs Ozempic (SEOB 026) (v5.0),SEOB 026,"ozemp , versu , vs",33.33333333,provid clinic differ ozemp wygovi,"ozempic,switch,transition",Switching from Ozempic (SEOB 065) (v7.0),SEOB 065,"ozemp , switch , transit",33.33333333,provid clinic differ ozemp wygovi,"2 mg,2.0 mg,ozempic,sustain forte",vs Ozempic 2 mg (SEOB 008) (v6.0),SEOB 008,"2 mg,2.0 mg , ozemp , sustain fort",25
76,REQ-43687,General,OSEM 137,"Please e-mail the following letters to HCP:
- Pipeline (GEN 090)
- Alzheimer's Disease (OSEM 137)

Many thanks,
Chuck Berds",not accurate,email follow letter hcp pipelin    gen 090    alzheim diseas    osem 137 thank chuck berd,pipeline,Pipeline (GEN 090) (v6.0),GEN 090,pipelin,100,email follow letter hcp pipelin    gen 090    alzheim diseas    osem 137 thank chuck berd,"product information,pi,package insert",PI Discussion (Verbal Response Only) (GEN 1001) (v2.0),GEN 1001,"product inform , pi , packag insert",33.33333333,email follow letter hcp pipelin    gen 090    alzheim diseas    osem 137 thank chuck berd,"hcp,additional information required,credentials,clarification,clarify,information",HCP Additional Information Required (GEN 130) (v2.0),GEN 130,"hcp , addit inform requir , credenti , clarif , clarifi , inform",16.66666667
77,,General,GEN 090,"Please e-mail the following letters to HCP:
- Pipeline (GEN 090)
- Alzheimer's Disease (OSEM 137)

Many thanks,
Chuck Berds",accurate with one of docID,email follow letter hcp pipelin    gen 090    alzheim diseas    osem 137 thank chuck berd,pipeline,Pipeline (GEN 090) (v6.0),GEN 090,pipelin,100,email follow letter hcp pipelin    gen 090    alzheim diseas    osem 137 thank chuck berd,"product information,pi,package insert",PI Discussion (Verbal Response Only) (GEN 1001) (v2.0),GEN 1001,"product inform , pi , packag insert",33.33333333,email follow letter hcp pipelin    gen 090    alzheim diseas    osem 137 thank chuck berd,"hcp,additional information required,credentials,clarification,clarify,information",HCP Additional Information Required (GEN 130) (v2.0),GEN 130,"hcp , addit inform requir , credenti , clarif , clarifi , inform",16.66666667
78,REQ-43691,Saxenda,SAX 093,"Please e-mail HCP with the following information:
- Binge Eating Disorder (SAX 093)

HCP also requesting publication:
1. Robert SA, Rohana AG, Shah SA, et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with l",accurate with one of docID,email hcp follow inform bing eat disord    sa 093 hcp request publication1 robert sa    rohana ag    shah sa    et al improv bing eat nondiabet obes individu 3 month treatment l,"binge eating disorder,binge eating,bed,bulimia",Binge Eating Disorder (SAX 093) (v7.0),SAX 093,"bing eat disord , bing eat , bed , bulimia",50,email hcp follow inform bing eat disord    sa 093 hcp request publication1 robert sa    rohana ag    shah sa    et al improv bing eat nondiabet obes individu 3 month treatment l,"study 1,prediabetes,obesity",Cover-SCALE Obesity and Prediabetes (SAX 003) (v8.0),SAX 003,"studi 1,prediabet , obes",33.33333333,email hcp follow inform bing eat disord    sa 093 hcp request publication1 robert sa    rohana ag    shah sa    et al improv bing eat nondiabet obes individu 3 month treatment l,"summary,overview,information,monograph",Product Overview (SAX 025) (v7.0),SAX 025,"summari , overview , inform , monograph",25
79,REQ-43692,Wegovy,SEOB 072,"Please e-mail the following letter to HCP:
- Pregnancy (SEOB 072)",accurate with one of docID,email follow letter hcp pregnanc    seob 072,"maintenance,dose,1.7,1.0,0.5,0.25,efficacy,low,lower",Weight - Doses Lower Than 2.4 mg (SEOB 055) (v4.0),SEOB 055,"mainten , dose,1.7,1.0,0.5,0.25,efficaci , low , low",12.5,email follow letter hcp pregnanc    seob 072,"pregnancy,pregnant,breastfeed,breastfed,lactation,fertility,fertile,teratogenicity,fetal,fetus,contraception,contraceptive",Pregnancy (SEOB 072) (v2.0),SEOB 072,"pregnanc , pregnant , breastfe , breastf , lactat , fertil , fertil , teratogen , fetal , fetu , contracept , contracept",10,email follow letter hcp pregnanc    seob 072,excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,excurs,0
80,REQ-43701,Rybelsus,OSEM 092,Doctor would like to receive information related to the efficacy of Rybelsus in patients with gastric bypass as it relates to possible interference with its absorption mechanism,not accurate,doctor like receiv inform relat efficaci rybelsu patient gastric bypass relat possibl interfer absorpt mechan,"moa,absorption,mechanism,snac,bioavailability",Media-Mechanism of Absorption (OSEM 3011) (v2.0),OSEM 3011,"moa , absorpt , mechan , snac , bioavail",40,doctor like receiv inform relat efficaci rybelsu patient gastric bypass relat possibl interfer absorpt mechan,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",25,doctor like receiv inform relat efficaci rybelsu patient gastric bypass relat possibl interfer absorpt mechan,"moa,action,mechanism,insulin,glucagon",Media-Mechanism of Action (OSEM 3012) (v2.0),OSEM 3012,"moa , action , mechan , insulin , glucagon",20
81,REQ-43702,Rybelsus,SEOB 025,Doctor would like to receive any information related to possible weight loss indication for oral semaglutide in the future.,accurate with one of docID,doctor like receiv inform relat possibl weight loss indic oral semaglutid futur,"weight,pound,kilogram,mechanism,weight loss",Mechanism of Weight Loss (OSEM 082) (v3.0),OSEM 082,"weight , pound , kilogram , mechan , weight loss",40,doctor like receiv inform relat possibl weight loss indic oral semaglutid futur,"oral,tablet,oasis,formulation",Oral Formulation (SEOB 025) (v5.0),SEOB 025,"oral , tablet , oasi , formul",25,doctor like receiv inform relat possibl weight loss indic oral semaglutid futur,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",20
82,REQ-43705,Ozempic,SEM 004,"Please send MI letter. On Ozempic and Diabetes retinopathy along with:
S Feldman et al, early worsening of diabetes retinopathy….(diabetes and metabolism, 44 (2018)
Bain et al, Worsening of diabetic retinopathy with rapid improvement in systemic glucose c",not accurate,send mi letter ozemp diabet retinopathi with feldman et al    earli worsen diabet retinopathi diabet metabol    44    2018 bain et al    worsen diabet retinopathi rapid improv system glucos c,"ozempic,glucose,semaglutide,fasting,fpg,preprandial",Fasting Plasma Glucose (FPG) (SEM 025) (v9.0),SEM 025,"ozemp , glucos , semaglutid , fast , fpg , preprandi",33.33333333,send mi letter ozemp diabet retinopathi with feldman et al    earli worsen diabet retinopathi diabet metabol    44    2018 bain et al    worsen diabet retinopathi rapid improv system glucos c,"type 1,diabetes,t1dm,t1d",Type 1 Diabetes (SEM 090) (v12.0),SEM 090,"type 1,diabet , t1 dm , t1d",25,send mi letter ozemp diabet retinopathi with feldman et al    earli worsen diabet retinopathi diabet metabol    44    2018 bain et al    worsen diabet retinopathi rapid improv system glucos c,"ozempic,semaglutide injection,drug,interaction",Drug Interactions (SEM 158) (v10.0),SEM 158,"ozemp , semaglutid inject , drug , interact",25
83,REQ-43709,Ozempic,SEM 174,What is the long-term data on weight loss for patients taking Ozempic?,not accurate,longterm datum weight loss patient take ozemp,"mechanism,weight,weight loss",Mechanism of Weight Loss (SEM 141) (v6.0),SEM 141,"mechan , weight , weight loss",66.66666667,longterm datum weight loss patient take ozemp,"weight,victoza",Weight vs. Victoza (SEM 142) (v6.0),SEM 142,"weight , victoza",50,longterm datum weight loss patient take ozemp,"obesity,weight",Obesity Indication (SEM 155) (v13.0),SEM 155,"obes , weight",50
84,REQ-43719,Saxenda,SAX 062,Is Saxenda contraindicated with a personal history of follicular thyroid cancer?,not accurate,saenda contraind person histori follicular thyroid cancer,"thyroid,thyroid neoplasms,mtc,men 2,calcitonin",Thyroid Neoplasms (SAX 018) (v1.0),SAX 018,"thyroid , thyroid neoplasm , mtc , man 2,calcitonin",20,saenda contraind person histori follicular thyroid cancer,"cancer,tumor,oncology,neoplasm,carcinoma,breast",Breast Neoplasms (SAX 010) (v7.0),SAX 010,"cancer , tumor , oncolog , neoplasm , carcinoma , breast",16.66666667,saenda contraind person histori follicular thyroid cancer,"pancreas,cancer,pancreatic,tumor,oncology,neoplasm,carcinoma",Pancreatic Cancer (SAX 015) (v7.0),SAX 015,"pancrea , cancer , pancreat , tumor , oncolog , neoplasm , carcinoma",14.28571429
85,REQ-43730,Saxenda,SAX 062,"A patient with a family history of thyroid cancer, unknown what kind in her mother.  She has regular thyroid labs. It is normal. What else do I need to monitor and at what frequency?  Also, what is a patient has had a thyroidectomy with cancer. Is she a c",not accurate,patient famili histori thyroid cancer    unknown kind mother    regular thyroid lab normal need monitor frequenc      patient thyroidectomi cancer c,"thyroid,thyroid neoplasms,mtc,men 2,calcitonin",Thyroid Neoplasms (SAX 018) (v1.0),SAX 018,"thyroid , thyroid neoplasm , mtc , man 2,calcitonin",20,patient famili histori thyroid cancer    unknown kind mother    regular thyroid lab normal need monitor frequenc      patient thyroidectomi cancer c,"cancer,tumor,oncology,neoplasm,carcinoma,breast",Breast Neoplasms (SAX 010) (v7.0),SAX 010,"cancer , tumor , oncolog , neoplasm , carcinoma , breast",16.66666667,patient famili histori thyroid cancer    unknown kind mother    regular thyroid lab normal need monitor frequenc      patient thyroidectomi cancer c,"pancreas,cancer,pancreatic,tumor,oncology,neoplasm,carcinoma",Pancreatic Cancer (SAX 015) (v7.0),SAX 015,"pancrea , cancer , pancreat , tumor , oncolog , neoplasm , carcinoma",14.28571429
86,REQ-43731,Rybelsus,OSEM 043,What data is there for semaglutide use and patients with CKD? Rybelsus or Ozempic,not accurate,datum semaglutid use patient ckd rybelsu ozemp,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",50,datum semaglutid use patient ckd rybelsu ozemp,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",40,datum semaglutid use patient ckd rybelsu ozemp,"glp-1 ra,glucagon-like peptide,safety,hypoglycemia,gastrointestinal,glutide,exenatide,victoza,trulicity,byetta,bydureon,ozempic,adlyxin",Safety vs Other GLP-1 RAs (OSEM 086) (v5.0),OSEM 086,"glp-1 ra , glucagon - like peptid , safeti , hypoglycemia , gastrointestin , glutid , exenatid , victoza , trulic , byetta , bydureon , ozemp , adlyxin",15.38461538
87,,Rybelsus,SEM 126,What data is there for semaglutide use and patients with CKD? Rybelsus or Ozempic,not accurate,datum semaglutid use patient ckd rybelsu ozemp,"safety,rybelsus,ozempic,ae",Safety vs Ozempic (OSEM 143) (v5.0),OSEM 143,"safeti , rybelsu , ozemp , ae",50,datum semaglutid use patient ckd rybelsu ozemp,"cv,rybelsus,ozempic,semglutide,indication",Rybelsus vs Ozempic-CV Indication (OSEM 133) (v5.0),OSEM 133,"cv , rybelsu , ozemp , semglutid , indic",40,datum semaglutid use patient ckd rybelsu ozemp,"glp-1 ra,glucagon-like peptide,safety,hypoglycemia,gastrointestinal,glutide,exenatide,victoza,trulicity,byetta,bydureon,ozempic,adlyxin",Safety vs Other GLP-1 RAs (OSEM 086) (v5.0),OSEM 086,"glp-1 ra , glucagon - like peptid , safeti , hypoglycemia , gastrointestin , glutid , exenatid , victoza , trulic , byetta , bydureon , ozemp , adlyxin",15.38461538
88,REQ-43734,Rybelsus,OSEM 072,Provider would like additional information on Rybelsus and pancreatitis. Recommend sending Ryblesus MI Infographic on pancreatitis.,accurate with one of docID,provid like addit inform rybelsu pancreat recommend send ryblesu mi infograph pancreat,"pancreatitis,amylase,lipase,pancreas,enzymes",Pancreatitis (OSEM 072) (v12.0),OSEM 072,"pancreat , amylas , lipas , pancrea , enzym",40,provid like addit inform rybelsu pancreat recommend send ryblesu mi infograph pancreat,"triglyceride,hypertriglyceridemia,pancreatitis",High Triglycerides and Pancreatitis (OSEM 079) (v5.0),OSEM 079,"triglycerid , hypertriglyceridemia , pancreat",33.33333333,provid like addit inform rybelsu pancreat recommend send ryblesu mi infograph pancreat,"ddi,di,interaction,levothyroxine,thyroid,omeprazole,ppi",Media-Drug Interactions Video (OSEM 3009) (v2.0),OSEM 3009,"ddi , di , interact , levothyroxin , thyroid , omeprazol , ppi",28.57142857
89,REQ-43735,Saxenda,SAX 080,HCP requested information on storage and stability for Saxenda.,accurate with one of docID,hcp request inform storag stabil saenda,"summary,overview,information,monograph",Product Overview (SAX 025) (v7.0),SAX 025,"summari , overview , inform , monograph",25,hcp request inform storag stabil saenda,"in-use,storage,stability,expiration,fridge,frozen,freeze,heat,hot,refrigerate,refrigeration,refrigerator,stable,store,temp,temperature,unopen,unopened,warm,room,cool,stored",Storage and Stability (SAX 080) (v4.0),SAX 080,#NAME?,11.11111111,hcp request inform storag stabil saenda,excursion,Cover to Excursion Data for Novo Nordisk Products (GEN 123) (v6.0),GEN 123,excurs,0
90,REQ-43737,Ozempic,SEM 016,Provider has pt who’s sister has medullary thyroid cancer and wants to know if she can give to her pt.,accurate with one of docID,provid pt s sister medullari thyroid cancer want know pt,"neoplasms,cancer,neoplasm",Neoplasms  (SEM 134) (v7.0),SEM 134,"neoplasm , cancer , neoplasm",50,provid pt s sister medullari thyroid cancer want know pt,"pancreatic,cancer,neoplasm,neoplasms,pancreas,pancreatic cancer",Pancreatic Cancer (SEM 032) (v9.0),SEM 032,"pancreat , cancer , neoplasm , neoplasm , pancrea , pancreat cancer",20,provid pt s sister medullari thyroid cancer want know pt,"thyroid,neoplasms,carcinoma,cancer,thyroid cancer,ptc,papillary thyroid carcinoma,mtc,medullary thyroid carcinoma,men2,men 2,multiple endocrine neoplasia syndrome type 2,neoplasia,follicular thyroid cancer,ftc",Thyroid Neoplasms (SEM 016) (v10.0),SEM 016,"thyroid , neoplasm , carcinoma , cancer , thyroid cancer , ptc , papillari thyroid carcinoma , mtc , medullari thyroid carcinoma , men2,men 2,multipl endocrin neoplasia syndrom type 2,neoplasia , follicular thyroid cancer , ftc",20
91,REQ-43742,Ozempic,SEM 008,Please send the MI letters SEM 007 (Antibodies) and SEM 008 (Allergic Reactions),accurate with one of docID,send mi letter sem 007    antibodi    sem 008    allerg reaction,"antibody,antibodies,immunogenicity",Antibodies (SEM 007) (v8.0),SEM 007,"antibodi , antibodi , immunogen",50,send mi letter sem 007    antibodi    sem 008    allerg reaction,"mechanism,protraction,moa,action",Mechanisms of Protraction and Action (SEM 018) (v7.0),SEM 018,"mechan , protract , moa , action",25,send mi letter sem 007    antibodi    sem 008    allerg reaction,"allergic,allergies,allergy,hypersensitivity,angioedema,anaphylactic,anaphylaxis,immunogenicity,reaction,reactions,skin,",Allergic Reactions (SEM 008) (v7.0),SEM 008,"allerg , allergi , allergi , hypersensit , angioedema , anaphylact , anaphylaxi , immunogen , reaction , reaction , skin ,",22.22222222
92,,Ozempic,SEM 007,Please send the MI letters SEM 007 (Antibodies) and SEM 008 (Allergic Reactions),accurate with one of docID,send mi letter sem 007    antibodi    sem 008    allerg reaction,"antibody,antibodies,immunogenicity",Antibodies (SEM 007) (v8.0),SEM 007,"antibodi , antibodi , immunogen",50,send mi letter sem 007    antibodi    sem 008    allerg reaction,"mechanism,protraction,moa,action",Mechanisms of Protraction and Action (SEM 018) (v7.0),SEM 018,"mechan , protract , moa , action",25,send mi letter sem 007    antibodi    sem 008    allerg reaction,"allergic,allergies,allergy,hypersensitivity,angioedema,anaphylactic,anaphylaxis,immunogenicity,reaction,reactions,skin,",Allergic Reactions (SEM 008) (v7.0),SEM 008,"allerg , allergi , allergi , hypersensit , angioedema , anaphylact , anaphylaxi , immunogen , reaction , reaction , skin ,",22.22222222
93,REQ-43743,Rybelsus,OSEM 044,Please send the MI letter OSEM 044 (Allergic Reactions),not accurate,send mi letter osem 044    allerg reaction,"moa,action,mechanism,insulin,glucagon",Media-Mechanism of Action (OSEM 3012) (v2.0),OSEM 3012,"moa , action , mechan , insulin , glucagon",20,send mi letter osem 044    allerg reaction,"mechanism,protraction,moa,action,mechanism of action",Mechanisms of Protraction and Action (OSEM 018) (v7.0),OSEM 018,"mechan , protract , moa , action , mechan action",20,send mi letter osem 044    allerg reaction,"cv,cardiovascular,mace,heart attack,mi,stroke,death,indication",CV Indication (OSEM 093) (v9.0),OSEM 093,"cv , cardiovascular , mace , heart attack , mi , stroke , death , indic",12.5
94,REQ-43747,Ozempic,SEM 1000,What are the baseline study medications used in Sustain 6? What were the specific Diabetes and CV standards of care used in the study and the breakdown? What were the specific oral antidiabetic treatments used?,not accurate,baselin studi medic sustain 6 specif diabet cv standard care studi breakdown specif oral antidiabet treatment,"cv,cardiovascular",SUSTAIN 6-CV Outcomes in Subgroup of Patients with CV Risk Factors (SEM 165) (v3.0),SEM 165,"cv , cardiovascular",50,baselin studi medic sustain 6 specif diabet cv standard care studi breakdown specif oral antidiabet treatment,"step,sustain,forte,diabetes,t2d",STEP 2 vs SUSTAIN FORTE (SEOB 057) (v1.0),SEOB 057,"step , sustain , fort , diabet , t2d",40,baselin studi medic sustain 6 specif diabet cv standard care studi breakdown specif oral antidiabet treatment,"sustain,trulicity,dulaglutide",Cover to SUSTAIN 7 (vs dulaglutide) (SEM 107) (v5.0),SEM 107,"sustain , trulic , dulaglutid",33.33333333
95,REQ-43748,Ozempic,SEM 109,Please send a copy of Sustain 9 study,accurate with one of docID,send copi sustain 9 studi,"sustain,sglt-2,sglt2,add,sustain 9,sustain 9",Cover to SUSTAIN 9 (add-on SGLT-2i) (SEM 109) (v5.0),SEM 109,"sustain , sglt-2,sglt2,add , sustain 9,sustain 9",40,send copi sustain 9 studi,"sustain,trulicity,dulaglutide",Cover to SUSTAIN 7 (vs dulaglutide) (SEM 107) (v5.0),SEM 107,"sustain , trulic , dulaglutid",33.33333333,send copi sustain 9 studi,"sustain,monotherapy,naive,treatment-naive",Cover to SUSTAIN 1 (monotherapy)  (SEM 101) (v6.0),SEM 101,"sustain , monotherapi , naiv , treatment - naiv",25
96,REQ-43749,Ozempic,SEM 1000,What are the baseline study medications used in Sustain 6? What were the specific Diabetes and CV standards of care used in the study and the breakdown? What were the specific oral antidiabetic treatments used?,not accurate,baselin studi medic sustain 6 specif diabet cv standard care studi breakdown specif oral antidiabet treatment,"cv,cardiovascular",SUSTAIN 6-CV Outcomes in Subgroup of Patients with CV Risk Factors (SEM 165) (v3.0),SEM 165,"cv , cardiovascular",50,baselin studi medic sustain 6 specif diabet cv standard care studi breakdown specif oral antidiabet treatment,"step,sustain,forte,diabetes,t2d",STEP 2 vs SUSTAIN FORTE (SEOB 057) (v1.0),SEOB 057,"step , sustain , fort , diabet , t2d",40,baselin studi medic sustain 6 specif diabet cv standard care studi breakdown specif oral antidiabet treatment,"sustain,trulicity,dulaglutide",Cover to SUSTAIN 7 (vs dulaglutide) (SEM 107) (v5.0),SEM 107,"sustain , trulic , dulaglutid",33.33333333
97,REQ-43750,Ozempic,SEM 109,Please send a copy of Sustain 9: Ozempic added on to SGLT2,accurate with one of docID,send copi sustain 9 ozemp add sglt2,"sustain,sglt-2,sglt2,add,sustain 9,sustain 9",Cover to SUSTAIN 9 (add-on SGLT-2i) (SEM 109) (v5.0),SEM 109,"sustain , sglt-2,sglt2,add , sustain 9,sustain 9",80,send copi sustain 9 ozemp add sglt2,"sustain,trulicity,dulaglutide",Cover to SUSTAIN 7 (vs dulaglutide) (SEM 107) (v5.0),SEM 107,"sustain , trulic , dulaglutid",33.33333333,send copi sustain 9 ozemp add sglt2,"sustain,monotherapy,naive,treatment-naive",Cover to SUSTAIN 1 (monotherapy)  (SEM 101) (v6.0),SEM 101,"sustain , monotherapi , naiv , treatment - naiv",25
98,REQ-43758,General,GEN 087,Wanted more info on investigator sponsored studies and who to contact,not accurate,want info investig sponsor studi contact,"contact,reach",Unable to Reach (GEN 104) (v6.0),GEN 104,"contact , reach",50,want info investig sponsor studi contact,"sunshine,act,transparency,payments",Transparency Guidelines (GEN 117) (v4.0),GEN 117,"sunshin , act , transpar , payment",25,want info investig sponsor studi contact,"trial,site,investigator,clinical trial site",Potential NNI Clinical Trial Investigator (GEN 032) (v5.0),GEN 032,"trial , site , investig , clinic trial site",25
